AGT and benign prostatic hyperplasia: Antithrombotic agents, calcium channel blockers, angiotensin II antagonists, lipid-modifying agents, and benign prostatic hypertrophy agents were only associated with an increased risk of FRIs in the case-crossover design and potentially have a transient effect on FRIs at the time of their initiation.